Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Degree of Housing Instability Shows Independent "Dose-Response" With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus.

Clemenzi-Allen A, Geng E, Christopoulos K, Hammer H, Buchbinder S, Havlir D, Gandhi M.

Open Forum Infect Dis. 2018 Mar 14;5(3):ofy035. doi: 10.1093/ofid/ofy035. eCollection 2018 Mar.

2.

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis.

Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY.

AIDS Patient Care STDS. 2018 Mar;32(3):104-111. doi: 10.1089/apc.2017.0255.

3.

Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Feb 3. doi: 10.1093/cid/ciy083. [Epub ahead of print]

PMID:
29415175
4.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

PMID:
29325070
5.

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.

Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY.

PLoS One. 2018 Jan 9;13(1):e0190118. doi: 10.1371/journal.pone.0190118. eCollection 2018.

6.

Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.

Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, Lifson JD, Fellay J, Deeks SG, Martin JN, Goedert JJ, Wolinsky SM, Michael NL, Kirk GD, Buchbinder S, Haas D, Ndung'u T, Goulder P, Parham P, Walker BD, Carlson JM, Carrington M.

Science. 2018 Jan 5;359(6371):86-90. doi: 10.1126/science.aam8825. Epub 2018 Jan 4.

PMID:
29302013
7.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

8.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

9.

Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the "Getting to Zero" Era.

Scheer S, Hsu L, Schwarcz S, Pipkin S, Havlir D, Buchbinder S, Hessol NA.

Clin Infect Dis. 2018 Mar 19;66(7):1027-1034. doi: 10.1093/cid/cix940.

PMID:
29099913
10.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

PMID:
29038282
11.

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

PMID:
28991887
12.

HIV testing and the care continuum among transgender women: population estimates from Rio de Janeiro, Brazil.

Jalil EM, Wilson EC, Luz PM, Velasque L, Moreira RI, Castro CV, Monteiro L, Garcia ACF, Cardoso SW, Coelho LE, McFarland W, Liu AY, Veloso VG, Buchbinder S, Grinsztejn B.

J Int AIDS Soc. 2017 Sep 19;20(1):21873. doi: 10.7448/IAS.20.1.21873.

13.

Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.

Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A.

AIDS. 2017 Oct 23;31(16):2245-2251. doi: 10.1097/QAD.0000000000001615.

PMID:
28832411
14.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.

PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.

15.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

PMID:
28639995
16.

CROI 2017: HIV Epidemic Trends and Advances in Prevention.

Liu AY, Buchbinder SP.

Top Antivir Med. 2017 May/Jun;25(2):35-50.

17.

International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status.

Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM.

Sex Transm Dis. 2017 May;44(5):306-309. doi: 10.1097/OLQ.0000000000000601.

PMID:
28407648
18.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

PMID:
28199679
19.

Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.

Grinsztejn B, Jalil EM, Monteiro L, Velasque L, Moreira RI, Garcia AC, Castro CV, Krüger A, Luz PM, Liu AY, McFarland W, Buchbinder S, Veloso VG, Wilson EC; Transcender Study Team.

Lancet HIV. 2017 Apr;4(4):e169-e176. doi: 10.1016/S2352-3018(17)30015-2. Epub 2017 Feb 8.

20.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM.

Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.

21.

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection.

Lama JR, Karuna ST, Grant SP, Swann EM, Ganoza C, Segura P, Montano SM, Lacherre M, De Rosa SC, Buchbinder S, Sanchez J, McElrath MJ, Lemos MP; HVTN 914 Study Team.

PLoS One. 2016 Aug 18;11(8):e0160487. doi: 10.1371/journal.pone.0160487. eCollection 2016.

22.

CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention.

Buchbinder SP, Liu AY.

Top Antivir Med. 2016 May-Jun;24(1):10-28. Review.

23.

Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia.

An P, Penugonda S, Thorball CW, Bartha I, Goedert JJ, Donfield S, Buchbinder S, Binns-Roemer E, Kirk GD, Zhang W, Fellay J, Yu XF, Winkler CA.

PLoS Genet. 2016 Mar 4;12(3):e1005921. doi: 10.1371/journal.pgen.1005921. eCollection 2016 Mar.

24.

Economic, Legal, and Social Hardships Associated with HIV Risk among Black Men who have Sex with Men in Six US Cities.

Nelson LE, Wilton L, Moineddin R, Zhang N, Siddiqi A, Sa T, Harawa N, Regan R, Dyer TP, Watson CC, Koblin B, Del Rio C, Buchbinder S, Wheeler DP, Mayer KH; HPTN 061 Study Team.

J Urban Health. 2016 Feb;93(1):170-88. doi: 10.1007/s11524-015-0020-y.

25.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

26.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

27.

Sexual Behavior and Network Characteristics and Their Association with Bacterial Sexually Transmitted Infections among Black Men Who Have Sex with Men in the United States.

Scott HM, Irvin R, Wilton L, Van Tieu H, Watson C, Magnus M, Chen I, Gaydos C, Hussen SA, Mannheimer S, Mayer K, Hessol NA, Buchbinder S.

PLoS One. 2015 Dec 31;10(12):e0146025. doi: 10.1371/journal.pone.0146025. eCollection 2015.

28.

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.

JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683.

29.

Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic.

Kinloch NN, MacMillan DR, Le AQ, Cotton LA, Bangsberg DR, Buchbinder S, Carrington M, Fuchs J, Harrigan PR, Koblin B, Kushel M, Markowitz M, Mayer K, Milloy MJ, Schechter MT, Wagner T, Walker BD, Carlson JM, Poon AF, Brumme ZL.

J Virol. 2015 Nov 11;90(3):1244-58. doi: 10.1128/JVI.02353-15. Print 2016 Feb 1.

30.

Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.

McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. doi: 10.1073/pnas.1514867112. Epub 2015 Nov 9.

31.

Acceptability and Feasibility of HIV Self-Testing Among Transgender Women in San Francisco: A Mixed Methods Pilot Study.

Lippman SA, Moran L, Sevelius J, Castillo LS, Ventura A, Treves-Kagan S, Buchbinder S.

AIDS Behav. 2016 Apr;20(4):928-38. doi: 10.1007/s10461-015-1236-2.

32.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

33.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

34.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

35.

Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities.

Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061.

PLoS One. 2015 Aug 4;10(8):e0134085. doi: 10.1371/journal.pone.0134085. eCollection 2015.

36.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network, Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A.

Open Forum Infect Dis. 2015 Jun 5;2(3):ofv082. doi: 10.1093/ofid/ofv082. eCollection 2015 Sep.

37.

Low-Grade Adenosquamous Carcinoma of the Breast Developing Around a Localization Wire Fragment.

Handa P, Khader SN, Buchbinder SS, Guelfguat M.

Lab Med. 2015 Summer;46(3):241-7. doi: 10.1309/LMKCX92LCJJ6BAIJ.

PMID:
26199266
38.

Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States.

Cohen SE, Vittinghoff E, Doblecki-Lewis S, Coleman M, Bacon O, Elion R, Kolber MA, Buchbinder S, Liu AY.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e33-5. doi: 10.1097/QAI.0000000000000716. No abstract available.

39.

Acceptability and feasibility of HIV self-testing among men who have sex with men in Peru and Brazil.

Volk JE, Lippman SA, Grinsztejn B, Lama JR, Fernandes NM, Gonzales P, Hessol NA, Buchbinder S.

Int J STD AIDS. 2016 Jun;27(7):531-6. doi: 10.1177/0956462415586676. Epub 2015 May 12.

40.

CROI 2015: Advances in HIV Testing and Prevention Strategies.

Buchbinder SP, Liu AY.

Top Antivir Med. 2015 Mar-Apr;23(1):8-27.

41.

Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.

Carnegie NB, Goodreau SM, Liu A, Vittinghoff E, Sanchez J, Lama JR, Buchbinder S.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):119-25. doi: 10.1097/QAI.0000000000000555.

42.

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM; Preexposure Prophylaxis Initiative Study Team.

Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.

43.

Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes.

Carlo Hojilla J, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, Liu AY.

AIDS Behav. 2016 Jul;20(7):1461-9. doi: 10.1007/s10461-015-1055-5.

44.

Client and provider perspectives on new HIV prevention tools for MSM in the Americas.

Lippman SA, Koester KA, Amico KR, Lama JR, Martinez Fernandes N, Gonzales P, Grinsztejn B, Liu A, Buchbinder S, Koblin BA.

PLoS One. 2015 Mar 31;10(3):e0121044. doi: 10.1371/journal.pone.0121044. eCollection 2015.

45.

Examining levels of risk behaviors among black men who have sex with Men (MSM) and the association with HIV acquisition.

Irvin R, Vallabhaneni S, Scott H, Williams JK, Wilton L, Li X, Buchbinder S; HPTN 061.

PLoS One. 2015 Feb 17;10(2):e0118281. doi: 10.1371/journal.pone.0118281. eCollection 2015.

46.

HIV infection.

Deeks SG, Overbaugh J, Phillips A, Buchbinder S.

Nat Rev Dis Primers. 2015 Oct 1;1:15035. doi: 10.1038/nrdp.2015.35. Review.

PMID:
27188527
47.

High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.

Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, Matheson T, Trainor N, Blue RW, Estrada Y, Coleman ME, Elion R, Castro JG, Chege W, Philip SS, Buchbinder S, Kolber MA, Liu AY.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):439-48. doi: 10.1097/QAI.0000000000000479.

48.

Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.

Liu AY, Hessol NA, Vittinghoff E, Amico KR, Kroboth E, Fuchs J, Irvin R, Sineath RC, Sanchez T, Sullivan PS, Buchbinder SP.

AIDS Patient Care STDS. 2014 Dec;28(12):622-7. doi: 10.1089/apc.2014.0195.

49.

When is good good enough for HIV-1 prophylaxis?

Buchbinder S.

Lancet Infect Dis. 2014 Nov;14(11):1024-1025. doi: 10.1016/S1473-3099(14)70959-4. Epub 2014 Oct 7. No abstract available.

PMID:
25300861
50.

Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.

Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R; iPrEx Study team.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):528-37. doi: 10.1097/QAI.0000000000000351.

Supplemental Content

Loading ...
Support Center